Genzyme Must Give NICE More Data To Avoid New European Problem For Aubagio
This article was originally published in The Pink Sheet Daily
Executive Summary
Britain’s NICE wants more data to address uncertainties about the clinical and cost-effectiveness of Genzyme’s oral MS drug Aubagio.